Home » Key Clinical Research Articles Global Medical Discovery » Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma

Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma

Zhang Y, Li Y, Deng J, Ji Z, Yu H, Li H. PLoS One. 2015 Feb 3;10(2):e0115896.

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.



To evaluate the clinical efficacy of sorafenib as preoperative neoadjuvant therapy in patients with high risk renal cell carcinoma (RCC).


Clinical data of 18 patients with high risk RCC who received surgery done successfully after preoperativeneoadjuvant therapy with sorafenib in Peking Union Medical College Hospital (PUMCH) from April 2007 to October 2013 have been reviewed and analyzed in this study.


Among the 18 patients there were 13 male and 5 female, with a median age of 54.6 years. The objective response rate (ORR) of the operation on the selected patients is very high (94.4%), including 4 cases (22.2%) of partial response (PR) and 13 cases (72.2%) of stable disease (SD). After preoperative sorafenib  treatment, the average tumor size of the 18 patients decreased from 7.8 cm (ranging from 3.6 to 19.2 cm) to 6.2 cm (ranging from 2.4 to 16.8 cm), and the median value of average tumor CT value decreased from 61HU to 52 HU. Among the 5 patients who had IVC tumor thrombi, the grades of tumor thrombi in 2 patients who were grade II before sorafenib treatment became grade I and grade 0 respectively, 2 patients of grade III both became grade II.


Preoperative neoadjuvant therapy with sorafenib for high risk RCC patients can significantly decrease primary tumor volume as well as tumor thrombus, which could help the nephron-sparing surgery (NSS) or radical nephrectomy to be done successfully.

Go To PubMed